Published in Curr Neuropharmacol on May 01, 2014
The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial. Schizophr Bull (2015) 0.99
From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry (2016) 0.82
System-based proteomic and metabonomic analysis of the Df(16)A(+/-) mouse identifies potential miR-185 targets and molecular pathway alterations. Mol Psychiatry (2016) 0.77
The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry (2016) 0.77
Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders. Front Neurol (2016) 0.76
Neuropil pruning in Early-Course Schizophrenia: Immunological, Clinical, and Neurocognitive Correlates. Biol Psychiatry Cogn Neurosci Neuroimaging (2016) 0.75
Asthma, corticosteroid use and schizophrenia: A nationwide population-based study in Taiwan. PLoS One (2017) 0.75
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res (2011) 5.39
Schizophrenia. Lancet (2004) 4.70
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Neurobiology of schizophrenia. Neuron (2006) 3.69
Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res (2009) 3.68
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2011) 3.33
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2007) 3.22
The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry (2006) 2.95
Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun (2001) 2.51
Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology (2010) 2.21
Cyclooxygenase-2: a therapeutic target. Annu Rev Med (2002) 2.16
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol (2005) 2.10
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2010) 1.90
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry (2009) 1.64
Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci (2010) 1.57
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging (2005) 1.52
A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull (2008) 1.49
Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus? Schizophr Res (1995) 1.44
Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci (2009) 1.43
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry (2004) 1.39
Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl) (2010) 1.29
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry (2002) 1.28
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res (2006) 1.25
C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res (2007) 1.25
IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci (2005) 1.25
Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull (2008) 1.21
Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res (1994) 1.20
Association of C-reactive protein with cognitive impairment. Arch Neurol (2010) 1.19
Immune System and Schizophrenia. Curr Immunol Rev (2010) 1.18
Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol (2005) 1.15
Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res (2003) 1.14
The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses (2001) 1.13
Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther (2011) 1.12
Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol (2008) 1.11
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res (2011) 1.08
Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res (2011) 1.07
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol (2013) 1.04
Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord (2012) 0.96
Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.96
The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl (2007) 0.96
Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. Am J Psychiatry (2011) 0.94
Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res (2012) 0.92
Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2004) 0.92
Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry (2004) 0.89
Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.85
Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett (2011) 0.84
Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opin Ther Targets (2008) 0.82
Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls. Brain Behav Immun (2013) 0.81
Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neurosci Lett (1999) 0.81
COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin Investig Drugs (2004) 0.81